Welcome to our dedicated page for Sellas Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SELLAS Life Sciences’ oncology pipeline is exciting—but its SEC paperwork can feel like a clinical protocol. Each annual report dissects Phase 3 GPS immunotherapy data, while 8-K material events flag trial pauses, licensing milestones, or new ATM financings. Tracking those disclosures—and the executive stock transactions Form 4 that sometimes precede them—takes time most investors don’t have.
That’s why Stock Titan brings every SELLAS Life Sciences quarterly earnings report 10-Q filing, insider trading Form 4 transactions and proxy statement executive compensation section into one AI-powered view. Our engine converts technical language into plain English, so understanding SELLAS Life Sciences SEC documents with AI becomes as direct as reading a headline. Need the latest SELLAS Life Sciences Form 4 insider transactions real-time? You’ll see alerts within minutes of EDGAR posting. Curious how cash burn compares Q-over-Q? The platform highlights the numbers for you, then links straight to the audited footnote.
- Instant summaries that make the SELLAS Life Sciences annual report 10-K simplified—focus on drug-development timelines, dilution risks and collaboration revenue.
- Auto-tagged sections so you can jump to “research & development expense” or “ASXL1 biomarker data” without scrolling 200 pages.
- Side-by-side analysis of every SELLAS Life Sciences earnings report filing analysis for trend spotting.
- One-click access to SELLAS Life Sciences 8-K material events explained, from FDA designations to financing agreements.
Whether you want SELLAS Life Sciences insider trading Form 4 transactions before the next 8-K, or just a clear view of how GPS milestones impact valuation, our real-time feed and concise AI commentary turn dense disclosures into actionable insight—no biotech PhD required.
Sellas Life Sciences Group, Inc. (SLS) received a Schedule 13G/A showing that Anson Funds Management LP and related Anson entities and principals collectively report beneficial ownership of 5,225,948 shares, representing 4.9% of the outstanding common stock on a fully diluted basis that includes shares underlying warrants. The reported share count uses 99,777,487 outstanding shares plus 4,950,948 shares issuable upon exercise of warrants to reach a 104,728,435 share denominator. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, and that exercise of warrants is subject to beneficial ownership limitations.
SELLAS Life Sciences Group, Inc. has filed a Form S-8 to register 800,000 additional shares of common stock for issuance under its Amended and Restated 2021 Employee Stock Purchase Plan. The increase of 800,000 shares was approved by the companys stockholders on June 17, 2025. The filing incorporates prior Form S-8 information by reference and includes customary legal and accounting consents and opinions.
SELLAS Life Sciences Group disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference, but the company states the press release is furnished and not deemed "filed" for purposes of certain securities laws.
The Form identifies the registrant and trading symbol SLS on Nasdaq, provides principal office contact details, and is signed by John T. Burns, Senior Vice President and Chief Financial Officer. The 8-K itself does not present the underlying financial figures; readers must consult Exhibit 99.1 for complete results and the corporate update.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on immunotherapies for hematologic and solid tumors. For the six months ended June 30, 2025, the company reported a net loss of $12.4 million, used $16.4 million of cash in operations, and had $25.3 million of cash and cash equivalents with an accumulated deficit of $260.5 million. Management states these resources are not expected to be sufficient for at least the next 12 months, and substantial doubt about going concern exists.
Clinically, the company reported positive developments: the REGAL Phase 3 GPS study's independent data monitoring committee recommended continuation after its interim review and the final analysis will occur at 80 events. Separately, SLS009 met primary endpoints in a Phase 2 study with an overall response rate of 33% (40% at the 30 mg BIW dose) and particularly strong responses in patients with ASXL1 mutations (50% ORR)$23.1 million.
The Form 8-K filed by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) discloses the voting results from the Company’s Annual Meeting held on June 17, 2025. Of the 94.5 million shares outstanding, 61.3 million (64.85%) were present or represented by proxy.
- Board elections: Class III directors Angelos M. Stergiou and John Varian were re-elected, receiving 83% and 84% of votes cast, respectively, excluding broker non-votes.
- Auditor ratification: Stockholders confirmed Baker Tilly US, LLP as independent auditor for FY 2025 with a strong 86.9% “For” vote.
- Equity plan amendment: An increase of 800,000 shares under the 2021 Employee Stock Purchase Plan was approved (66% “For”).
- Say-on-pay: The advisory resolution on executive compensation passed with 69% support.
- Say-on-frequency: A plurality of holders (74%) preferred an annual vote on executive compensation.
- Adjournment authority: Shareholders granted the Board discretion to adjourn the meeting if additional proxy solicitation were needed.
No other matters were presented, and no financial performance data or strategic transactions were reported in this filing.